Cardiac Muscle & Receptors

📋 Key Information Summary

📋

Cardiac myocytes exhibit four intrinsic electrophysiological properties — automaticity, excitability (conductivity in some texts), conductivity, and contractility — which together sustain rhythmic, coordinated ventricular contraction.
The ventricular action potential has five phases (0–4); Phase 4 in working myocytes is normally stable, while pacemaker cells exhibit spontaneous diastolic depolarisation driven by the funny current (I_f).
Sympathetic activation via β₁-adrenergic receptors increases heart rate (chronotropy), contractility (inotropy), conduction velocity (dromotropy), and relaxation rate (lusitropy) through G_s–cAMP–PKA signalling.
β₂-adrenergic receptors are present in human myocardium but at lower density than β₁ (ratio ≈ 70:30); they mediate vasodilatation, bronchodilatation, and contribute to inotropy at high catecholamine concentrations.
α₁-adrenergic receptors activate G_q–PLC–IP₃/DAG signalling causing vasoconstriction, modest positive inotropy (especially in failing myocardium), and myocardial hypertrophy when chronically stimulated.
Parasympathetic (vagal) influence acts via M₂ muscarinic receptors coupled to G_i, reducing cAMP and activating I_KACh to produce bradycardia, reduced atrial contractility, and attenuated AV-nodal conduction.
β-blockers (metoprolol, bisoprolol, carvedilol) reduce mortality in heart failure with reduced ejection fraction (HFrEF) by reversing chronic β₁-receptor downregulation and desensitisation.
Atropine (M₂ antagonist) is first-line for symptomatic bradycardia; adrenaline (mixed adrenergic agonist) is first-line in cardiac arrest per Australian Resuscitation Council (ARC) guidelines.
Pharmacological receptor selectivity is dose-dependent — high-dose adrenaline activates α₁, β₁, and β₂ receptors, whereas low-dose infusion is predominantly β-mediated.
Understanding receptor physiology is essential for rational use of inotropes, vasopressors, chronotropes, and antiarrhythmics in Australian emergency and critical-care settings.
Chronic sympathetic overdrive leads to β₁-receptor downregulation and G-protein uncoupling — the rationale for initiating β-blockers at low dose in HFrEF and up-titrating slowly over weeks.
Aboriginal and Torres Strait Islander Australians experience cardiovascular disease at 1.7× the rate of non-Indigenous Australians; receptor-targeted therapies must be accessible in rural and remote settings.

Introduction & Australian Epidemiology

Cardiac muscle possesses four fundamental electrophysiological properties that distinguish it from skeletal and smooth muscle: automaticity (spontaneous impulse generation by pacemaker cells), excitability (the ability to respond to a stimulus), conductivity (propagation of the action potential through the syncytium), and contractility (force generation in response to depolarisation). The interplay of these properties, modulated by the autonomic nervous system through adrenergic and muscarinic receptors, underpins virtually every pharmacological intervention used in contemporary Australian cardiology practice.

Cardiovascular disease remains the leading cause of death in Australia, accounting for approximately 26% of all deaths in 2022 (Australian Bureau of Statistics). Heart failure alone affects an estimated 480 000 Australians, with prevalence rising sharply after age 65 years (AIHW, 2023). Ischaemic heart disease, hypertensive heart disease, and cardiomyopathies all converge on alterations in cardiac muscle electrophysiology and receptor signalling, making a thorough understanding of these systems essential for evidence-based prescribing.

This guideline reviews cardiac muscle physiology, the major adrenergic receptor subtypes (α₁, β₁, β₂), muscarinic receptor (M₂) autonomic control, and the pharmacological implications relevant to Australian primary-care and specialist practice. All drug references align with the Pharmaceutical Benefits Scheme (PBS) and current Australian therapeutic standards.

📊

Australian context: Approximately 1.2 million prescriptions for β-blockers are dispensed under the PBS annually. Heart failure hospitalisations total over 70 000 per year, costing the Australian health system an estimated .7 billion (AIHW 2023). Optimising receptor-targeted therapy is a national priority.

Cardiac Muscle Physiology (Action Potential)

The cardiac action potential differs markedly between pacemaker cells (SA node, AV node) and working ventricular myocytes. Understanding both is essential because the receptor-mediated modulation of each phase determines the clinical effect of adrenergic and muscarinic agonists and antagonists.

Ventricular Myocyte Action Potential (Fast-Response)

Phase	Name	Ionic Basis	Receptor Modulation
Phase 0	Rapid depolarisation	Na⁺ influx via voltage-gated I_Na channels	β₁-agonism ↑ Na⁺ channel availability; Class I antiarrhythmics block I_Na
Phase 1	Early repolarisation	Transient K⁺ efflux (I_to)	Modest adrenergic modulation of I_to
Phase 2	Plateau	Balance between Ca²⁺ influx (I_CaL) and K⁺ efflux	β₁ ↑ I_CaL via PKA phosphorylation → ↑ contractility; β-blockers attenuate this
Phase 3	Repolarisation	K⁺ efflux via I_Kr and I_Ks	β₁ ↑ I_Ks → shortened APD at high HR; M₂ ↑ I_KACh in atria
Phase 4	Resting membrane potential	K⁺ equilibrium (≈ −90 mV); Na⁺/K⁺-ATPase	Stable in working myocytes; β₁ increases Ca²⁺ leak → arrhythmia risk

Pacemaker Cell Action Potential (Slow-Response, SA Node)

Pacemaker cells lack fast Na⁺ channels. Their action potential depends on:

Phase 4 — Spontaneous diastolic depolarisation: Driven primarily by the funny current (I_f, a mixed Na⁺/K⁺ current activated by hyperpolarisation), T-type Ca²⁺ channels, and decay of outward K⁺ current. This is the basis of automaticity.
Phase 0 — Upstroke: Ca²⁺ influx through L-type (I_CaL) and T-type (I_CaT) calcium channels — slower and of lower amplitude than ventricular Phase 0.
Phase 3 — Repolarisation: K⁺ efflux via I_K channels.

🔑

Key receptor link: β₁-agonism (sympathetic) accelerates Phase 4 diastolic depolarisation by increasing I_f and I_CaL → positive chronotropy (↑ heart rate). M₂-agonism (vagal) slows Phase 4 by reducing I_f and activating I_KACh → negative chronotropy (↓ heart rate). This is the primary mechanism by which the autonomic nervous system controls heart rate.

Excitation–Contraction Coupling

Depolarisation opens voltage-gated L-type Ca²⁺ channels (Phase 2), admitting a small Ca²⁺ influx that triggers a much larger release of Ca²⁺ from the sarcoplasmic reticulum (SR) via ryanodine receptors (RyR2) — a process termed calcium-induced calcium release (CICR). Cytoplasmic Ca²⁺ binds troponin C, displacing tropomyosin and permitting actin–myosin cross-bridge cycling. β₁-adrenergic stimulation enhances this cascade at multiple points:

↑ I_CaL → more trigger Ca²⁺
Phosphorylation of phospholamban → disinhibition of SERCA2a → faster SR Ca²⁺ reuptake → positive lusitropy (enhanced relaxation)
Phosphorylation of RyR2 → increased SR Ca²⁺ release sensitivity
Phosphorylation of troponin I → reduced myofilament Ca²⁺ sensitivity → faster cross-bridge detachment

Adrenergic Receptors (Alpha, Beta-1, Beta-2)

Adrenergic receptors are G-protein-coupled receptors (GPCRs) activated by endogenous catecholamines (noradrenaline, adrenaline, dopamine) and by exogenous sympathomimetic drugs. Three principal subtypes are clinically relevant in cardiovascular medicine.

Receptor	G-Protein	Second Messenger	Primary Cardiac / Vascular Effects	Endogenous Affinity
α₁	G_q	↑ IP₃ / DAG → ↑ intracellular Ca²⁺	Vasoconstriction (arteriolar smooth muscle); modest positive inotropy; myocardial hypertrophy with chronic stimulation	Adrenaline ≥ Noradrenaline
β₁	G_s	↑ cAMP → ↑ PKA	↑ Heart rate (chronotropy); ↑ contractility (inotropy); ↑ conduction velocity (dromotropy); ↑ relaxation rate (lusitropy); ↑ renin release	Noradrenaline ≈ Adrenaline
β₂	G_s (also G_i at high conc.)	↑ cAMP; vasodilatation, bronchodilatation	Vascular smooth-muscle relaxation; bronchodilatation; hepatic glycogenolysis; mild positive inotropy in ventricle; hypokalaemia (skeletal muscle K⁺ uptake)	Adrenaline >> Noradrenaline

β₁-Adrenergic Receptors — The Dominant Cardiac Receptor

Approximately 70–80% of β-receptors in the healthy human ventricle are β₁-subtype, localised predominantly at the T-tubule junction near L-type Ca²⁺ channels and at the Z-line adjacent to RyR2 clusters. This spatial coupling ensures that cAMP/PKA signalling is delivered precisely to excitation–contraction coupling machinery.

In chronic heart failure, persistent sympathetic activation (plasma noradrenaline is typically elevated 2–3-fold) leads to β₁-receptor downregulation (reduced receptor density) and desensitisation (GRK-mediated phosphorylation → β-arrestin recruitment → uncoupling from G_s). This is the pathophysiological rationale for β-blocker therapy in HFrEF — by reducing chronic catecholamine drive, β-blockers permit receptor density to recover, restoring physiological responsiveness.

β₂-Adrenergic Receptors

Although comprising only ~20–30% of cardiac β-receptors, β₂-subtypes gain functional importance in heart failure (where β₁ is downregulated) and during high-dose catecholamine infusion. β₂ receptors couple to both G_s and G_i; the latter can activate cardioprotective pathways (PI3K–Akt) but also promote arrhythmogenesis via spatially restricted cAMP microdomains. In clinical practice, β₂ effects are exploited therapeutically by salbutamol (bronchodilatation) and must be recognised as a cause of tachycardia and hypokalaemia.

α₁-Adrenergic Receptors

α₁-receptors are the dominant vasoconstrictor adrenergic receptors in arteriolar smooth muscle, mediating the pressor response to noradrenaline and phenylephrine. In the myocardium, α₁-receptors (predominantly α₁A and α₁B subtypes) couple to G_q–PLC, generating IP₃ (sarcoplasmic reticulum Ca²⁺ release) and DAG (PKC activation). The net effect is a modest positive inotropic response that is independent of cAMP and therefore additive to β₁-mediated inotropy. Chronic α₁-stimulation activates foetal gene programmes (ANP, β-MHC) contributing to pathological hypertrophy.

⚠️

Clinical pearl — Phenylephrine in anaesthesia: Phenylephrine is a selective α₁-agonist used to treat intraoperative hypotension. While it raises blood pressure via vasoconstriction, it can cause reflex bradycardia (baroreceptor-mediated vagal activation) and reduce cardiac output in patients with impaired ventricular function. In patients with HFrEF, noradrenaline (mixed α₁/β₁) is preferred in shock states.

Receptor Selectivity Is Dose-Dependent

A critical pharmacological principle is that receptor selectivity diminishes at high doses:

Adrenaline: Low dose (0.01–0.03 µg/kg/min) → predominantly β₁/β₂ (↑ HR, ↑ CO, vasodilatation). High dose (>0.15 µg/kg/min) → α₁ predominates (vasoconstriction, ↑ SVR).
Noradrenaline: Predominantly α₁ and β₁ across all doses; minimal β₂ activity — hence causes vasoconstriction without significant bronchodilatation.
Dobutamine: Predominantly β₁ with some β₂ and α₁; net effect is ↑ contractility with modest ↓ SVR.

Muscarinic Receptors & Autonomic Control

The parasympathetic nervous system modulates cardiac function primarily through acetylcholine (ACh) acting on M₂ muscarinic receptors located on SA-node pacemaker cells, atrial myocytes, and AV-nodal conduction tissue. The ventricles have sparse vagal innervation, so parasympathetic effects on ventricular contractility are indirect (mediated via sympathetic withdrawal and presynaptic inhibition of noradrenaline release).

M₂ Receptor Signalling Cascade

G-protein coupling: G_i (inhibitory) — directly inhibits adenylyl cyclase → ↓ cAMP → ↓ PKA activity.
Gβγ subunit: Opens I_KACh (G-protein-gated inward-rectifier K⁺ channels) → membrane hyperpolarisation → slowed Phase 4 diastolic depolarisation → negative chronotropy.
AV node: ↓ cAMP and ↑ I_KACh slow conduction velocity and prolong refractory period → negative dromotropy (slowed AV conduction, risk of AV block at high vagal tone).
Atria: ↓ I_CaL and ↑ I_KACh reduce atrial contractility and shorten atrial action potential duration.
Presynaptic M₂/M₄: Inhibit noradrenaline release from sympathetic nerve terminals — a key mechanism of vagal–sympathetic interaction.

Vagal Tone and Heart Rate Variability

Resting heart rate in healthy adults (60–80 bpm) reflects tonic vagal dominance over sympathetic drive — a phenomenon termed vagal tone. High vagal tone (e.g., in trained athletes) produces resting bradycardia. Loss of vagal tone — as in autonomic neuropathy (diabetes), post-cardiac transplant, or with anticholinergic drugs — results in an elevated resting heart rate with reduced heart rate variability (HRV), an independent predictor of cardiovascular mortality.

💡

Vasovagal syncope: Sudden excessive vagal discharge causes profound bradycardia and/or hypotension. First-line management includes physical counter-pressure manoeuvres (leg crossing, handgrip). Atropine 600 µg IV is used if bradycardia is severe and symptomatic.

Other Muscarinic Subtypes (Brief Overview)

Subtype	Location	Cardiovascular Relevance
M₁	Autonomic ganglia, CNS	Minimal direct cardiac role; relevant to cognitive side-effects of anticholinergics
M₂	SA node, AV node, atria	Primary cardiac parasympathetic receptor — negative chronotropy, dromotropy
M₃	Vascular endothelium, smooth muscle	Endothelial M₃ → NO release → vasodilatation; smooth muscle M₃ → vasoconstriction
M₄, M₅	CNS	No direct cardiovascular role

Pharmacological Implications

Knowledge of receptor subtypes, G-protein coupling, and downstream signalling directly informs prescribing decisions across the spectrum of cardiovascular medicine. Below are clinically important drug classes mapped to their receptor targets.

Sympathomimetics (Adrenergic Agonists)

💊

Adrenaline

DBL Adrenaline® · Non-selective α + β agonist

Adult dose Cardiac arrest: 1 mg IV every 3–5 min (ARC); Anaphylaxis: 500 µg IM (0.5 mL of 1:1000); Septic shock infusion: 0.01–0.5 µg/kg/min IV

Paediatric dose Cardiac arrest: 10 µg/kg IV/IO (max 1 mg); Anaphylaxis: 10 µg/kg IM (max 500 µg)

Route / Frequency IV bolus (cardiac arrest); IM (anaphylaxis); IV infusion (shock)

Key receptor effects Low dose → β₁/β₂ (↑HR, ↑CO, vasodilatation); High dose → α₁ predominates (vasoconstriction)

PBS status ✔ PBS General Benefit

💊

Noradrenaline

DBL Noradrenaline® · α₁ + β₁ agonist

Adult dose Septic shock: 0.01–0.5 µg/kg/min IV infusion, titrate to MAP ≥ 65 mmHg

Key receptor effects α₁ → vasoconstriction (↑ SVR); β₁ → ↑ contractility; minimal β₂

PBS status ✔ PBS General Benefit

💊

Dobutamine

DBL Dobutamine® · Predominantly β₁ agonist

Adult dose 2.5–20 µg/kg/min IV infusion; titrate to cardiac output

Key receptor effects β₁ → ↑ contractility (inotropy); some β₂ → ↓ SVR; mild α₁

PBS status ✔ PBS General Benefit

💊

Phenylephrine

Phenylephrine injection · Selective α₁ agonist

Adult dose Intraoperative hypotension: 100–200 µg IV bolus; Infusion: 0.5–5 µg/kg/min

Key receptor effects α₁ only → vasoconstriction → ↑ SVR and MAP; reflex bradycardia

PBS status ✔ PBS General Benefit

β-Blockers (Adrenergic Antagonists)

💊

Metoprolol succinate

Betaloc CR® · Seloken® · Cardioselective β₁-blocker

Adult dose (HFrEF) Start 23.75 mg PO daily; ↑ every 2 weeks to target 190 mg daily

Adult dose (AF rate control) 50–200 mg PO daily (immediate-release 25–100 mg BD)

Renal adjustment Not required — hepatic elimination

Key receptor effects β₁ selective → ↓HR, ↓contractility, ↓AV conduction; β₂ effects minimal at standard doses

PBS status ✔ PBS General Benefit

💊

Bisoprolol

Bicor® · Cardioselective β₁-blocker

Adult dose (HFrEF) Start 1.25 mg PO daily; ↑ every 2 weeks to target 10 mg daily

Key receptor effects High β₁ selectivity (~75:1 β₁:β₂); reduces mortality in HFrEF by reversing receptor downregulation

PBS status ✔ PBS General Benefit

💊

Carvedilol

Dilatrend® · Non-selective β + α₁ blocker

Adult dose (HFrEF) Start 3.125 mg PO BD; ↑ every 2 weeks to target 25 mg BD (50 mg BD if >85 kg)

Key receptor effects β₁ + β₂ blockade + α₁ blockade → ↓HR, ↓BP (vasodilatory component), antioxidant properties

PBS status ✔ PBS General Benefit

Anticholinergics (Muscarinic Antagonists)

💊

Atropine sulfate

Atropine injection · Non-selective muscarinic antagonist

Adult dose Symptomatic bradycardia: 600 µg IV, repeat every 3–5 min (max 3 mg); ACLS asystole/PEA: 1 mg IV

Paediatric dose 20 µg/kg IV (min 100 µg, max 600 µg); repeat once

Key receptor effects Blocks M₂ → removes vagal inhibition → ↑ SA automaticity, ↑ AV conduction

PBS status ✔ PBS General Benefit

🚨

Do not use atropine in cardiac transplant patients. The transplanted heart is denervated and relies on circulating catecholamines rather than vagal tone; atropine is ineffective and may worsen ischaemia through tachycardia without benefit. Use isoprenaline or direct cardiac pacing instead.

Receptor-Targeted Therapy Quick Reference

Bradycardia (symptomatic)

Atropine 600 µg IV

Repeat q3–5 min

Blocks M₂ vagal effect

HFrEF (NYHA II–IV)

β-blocker + ACEi/ARB + MRA ± SGLT2i

Ongoing

Recovers downregulated β₁ receptors

Septic shock

Noradrenaline 1st line (α₁ + β₁)

ICU infusion

Add dobutamine if ↓CO persists

Anaphylaxis

Adrenaline 500 µg IM

Repeat q5 min PRN

α₁ → ↓oedema; β₁ → ↑CO; β₂ → bronchodilatation

AF with RVR

Metoprolol or diltiazem

Rate target <110 bpm

β₁ blockade ↓ AV conduction

Investigations

While receptor physiology is primarily an applied-pharmacology topic, several investigations are relevant when assessing autonomic function or titrating receptor-targeted therapies.

Available

12-lead ECG

Assess baseline HR, PR interval (AV conduction), QTc (Class III drug monitoring). MBS Item 11700.

Available

Echocardiography

LVEF for HFrEF diagnosis and β-blocker initiation. MBS Item 55120 (if clinical indication).

Available

BNP / NT-proBNP

Heart failure diagnosis, severity grading, and monitoring response to β-blocker/ACEi therapy.

Available

24-hour Holter monitor

Heart rate variability (HRV) analysis as a marker of autonomic balance; AF burden quantification. MBS Item 11706.

Referral

Tilt-table test

Diagnosis of vasovagal syncope; performed in cardiology/electrophysiology units.

Specialist

Sympathetic nerve microneurography / plasma catecholamines

Research and specialised centres; quantify sympathetic overdrive in heart failure.

Available

Serum electrolytes (K⁺, Mg²⁺)

β₂-agonist-induced hypokalaemia monitoring (salbutamol, adrenaline infusion). Essential before IV digoxin.

Special Populations

🤰 Pregnancy

Labetalol

Preferred β-blocker in pregnancy (α₁ + β-blocker); safe in all trimesters. 1st-line for pre-eclampsia-related hypertension.

Metoprolol

Acceptable alternative β₁-blocker; monitor for fetal bradycardia and IUGR with prolonged use.

Atenolol

Avoid — associated with fetal IUGR when used in 1st trimester.

👶 Paediatrics

Adrenaline (anaphylaxis)

10 µg/kg IM (max 500 µg). EpiPen® Jr (150 µg) for children 7.5–25 kg.

Atropine

20 µg/kg IV (min 100 µg, max 600 µg) for symptomatic bradycardia.

Propranolol

Used for infantile haemangioma (PBS Authority Required) — demonstrates β₂-mediated vasoconstriction and endothelial regression.

👴 Elderly

β-blockers

Increased risk of bradycardia and hypotension; start at lowest dose, monitor HR and BP closely. Age-related decline in β-receptor responsiveness (reduced G_s coupling).

Anticholinergics

Avoid atropine in delirium-prone elderly; anticholinergic burden contributes to cognitive impairment.

🫘 Renal Impairment

Metoprolol

Hepatically metabolised — no dose adjustment required; preferred in CKD.

Atenolol

Renally cleared — dose reduction required in CKD (avoid in eGFR <15); significant accumulation risk.

🫁 Hepatic Impairment

Carvedilol

Hepatically metabolised; significantly increased bioavailability in cirrhosis — reduce dose and monitor closely. Avoid in severe hepatic impairment.

Bisoprolol

Equal renal/hepatic elimination — use with caution in severe liver disease.

🛡️ Immunocompromised

β-blockers

Generally safe in immunocompromised patients; be aware of drug interactions with calcineurin inhibitors (cyclosporin, tacrolimus) — both reduce heart rate via different mechanisms.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience cardiovascular disease at approximately 1.7 times the rate of non-Indigenous Australians, with premature onset (10–20 years earlier) and higher case-fatality rates (AIHW, 2023). Rheumatic heart disease (RHD) remains a significant burden, particularly in Northern Australia, and directly impacts cardiac muscle function and receptor-mediated physiology through chronic valvular pathology and myocardial remodelling.

RHD prevalence

RHD affects Indigenous Australians at 5–7 times the rate of non-Indigenous Australians, primarily in the NT, QLD, and WA. Chronic rheumatic carditis leads to β-receptor remodelling and heart failure requiring β-blocker therapy (RHDAustralia guidelines).

Remote access to care

Many communities rely on remote-area nurses and visiting medical officers. β-blocker initiation and dose titration for HFrEF requires structured follow-up (e.g., telehealth cardiology review via MBS Items 91822/91823).

PBS access

All PBS-listed β-blockers and cardiac medications are available through Closing the Gap PBS co-payment measure — patients pay a maximum of .70 per script (2024), reducing out-of-pocket barriers.

Cultural safety

Pharmacological education should be delivered through Aboriginal Health Workers/Practitioners (AHW/Ps) in culturally appropriate settings. Medication adherence programmes should incorporate family and community engagement.

RHD secondary prophylaxis

Benzathine penicillin G (BPG) 1.2 MU IM every 21–28 days is the cornerstone of RHD secondary prophylaxis. Understanding vagal and muscarinic effects is relevant when managing injection-related pain and vasovagal episodes during BPG administration.

Anaphylaxis preparedness

Adrenaline autoinjectors (EpiPen®) should be available in remote health centres. Training AHWs in IM adrenaline administration (receptor pharmacology: α₁/β₁/β₂) is essential for managing anaphylaxis from medications and envenomation.

⚠️

RHD and heart failure: Indigenous Australians with RHD-related heart failure are often younger and may have preserved ejection fraction initially. β-blocker therapy should still be considered early in the disease trajectory, with dose titration guided by symptom response and echocardiographic monitoring. Refer to RHDAustralia (www.rhdaustralia.org.au) for condition-specific guidance.

📚 References

1. Australian Institute of Health and Welfare (AIHW). Heart, stroke and vascular disease — Australian facts 2023. Canberra: AIHW; 2023.
2. McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007.
4. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–1658.
5. Australian Resuscitation Council (ARC). Guideline 11.2 – Protocols for adult advanced life support. ARC; 2024. Available from: https://resus.org.au
6. Brodde O-E, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999;51(4):651–690.
7. Bristow MR, Ginsburg R, Umans V, et al. β₁- and β₂-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β₁-receptor downregulation in heart failure. Circ Res. 1986;59(3):297–309.
8. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand. Guidelines for the prevention, detection, and management of heart failure in Australia 2018. Updated 2024.
9. RHDAustralia (a program of Menzies School of Health Research). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: RHDAustralia; 2020.
10. Rhee EP, Berk BC. Adrenergic receptors and the failing heart. In: Heart Failure: A Companion to Braunwald's Heart Disease. 4th ed. Elsevier; 2020:141–157.
11. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
12. Pharmaceutical Benefits Scheme (PBS). Australian Government Department of Health and Aged Care. Available from: https://www.pbs.gov.au. Accessed 2024.